Furthermore, recombinant GDF15 or GDF15 overexpression ameliorated NASH and related metabolic disorders in mice by alleviating hepatic inflammatory response and modulating lipid metabolism and β-oxidation of fatty acids, which was independently of reduction in body mass (66, 67). This evidence concerns the gene GDF15 and Other metabolic disease.